Skip to search formSkip to main contentSkip to account menu

NSC 366140

Known as: NSC-366140 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
PD115934 (NSC 366140) is a soluble pyrazoloacridine derivative presently undergoing preclinical toxicology evaluation with the… 
2004
2004
Pyrazoloacridine (PZA) is an experimental antitumor agent presently under investigation for treatment of solid tumors on the… 
2004
2004
AbstractBackground: Pyrazoloacridine (PZA) is thefirst of a new class of rationallysynthesized acridine derivatives to… 
Highly Cited
1998
Highly Cited
1998
Pyrazoloacridine (PA), an acridine congener with an unknown mechanism of action, has shown selective activity against solid tumor… 
1997
1997
Pyrazoloacridine (PA), an acridine congener that has shown selective toxicity in solid tumor cells, full activity against… 
1996
1996
Purpose. Pyrazoloacridine (PZA) is a newly developed anticancer agent currently undergoing clinical trials. Its mode of action… 
1995
1995
Pharmacokinetic studies that consisted of measuring the plasma drug profile, tissue drug distribution, and elimination in urine… 
Highly Cited
1994
Highly Cited
1994
BACKGROUND 9-Methoxypyrazoloacridine (PZA) is an anticancer agent that shows selectivity of action for carcinomas over leukemias… 
Highly Cited
1990
Highly Cited
1990
PD115934 (NSC 366140) is a soluble pyrazoloacridine derivative presently undergoing preclinical toxicology evaluation with the… 
Highly Cited
1989
Highly Cited
1989
  • R. Jackson
  • Advances in enzyme regulation
  • 1989
  • Corpus ID: 20436355